早期发现阿尔茨海默病:对机器学习技术的审查,以预测从轻度认知障碍到轻度认知障碍的过渡
Soraisam Gobinkumar Singh1, Dulumani Das1, Utpal Barman1
1Faculty of Computer Technology, Assam down town University, Guwahati 781026, Assam, India.
Diagnostics (Basel, Switzerland)
|August 29, 2024
概括
机器学习准确地预测了阿尔茨海默病从轻度认知障碍转变为阿尔茨海默病. 这篇评论探讨了深度学习和其他人工智能方法,使用神经成像和生物标志物进行早期检测.
科学领域:
- 神经科学和人工智能 人工智能
- 生物医学成像和机器学习
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响认知.
- 早期发现轻度认知障碍 (MCI) 转化为AD是及时干预的关键.
- 机器学习 (ML),特别是深度学习 (DL),显示出预测这种转换的潜力.
研究的目的:
- 审查和综合有关ML方法的当前研究,以预测MCI转化为AD痴呆的方法.
- 检查各种ML技术,包括DL和转移学习,应用于AD预测.
- 讨论在AD检测研究中使用的数据模式和特征提取方法.
主要方法:
- 系统审查关于ML的文献,以预测阿尔茨海默病的疾病.
- 分析使用磁共振成像 (MRI),正子发射断层扫描 (PET) 和其他生物标志物的研究.
- 检查各种ML算法,深度学习架构和功能工程技术.
主要成果:
- ML和DL模型在识别患有MCI转化为AD风险的个体方面显示出显著的前景.
- 多模式数据集成 (如MRI,PET) 往往可以提高预测准确度.
- 各种特征提取方法有助于预测模型的性能.
结论:
- 机器学习为早期检测阿尔茨海默病进展提供了一个强大的工具包.
- 需要进一步的研究来完善模型,验证不同队列的发现,并探索新的生物标志物.
- 本综述强调了关键的进展,并概述了人工智能驱动的阿尔茨海默氏症诊断的未来方向.
关键词:
AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD ADD was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在MCI中,MCI是MCI.这就是为什么MRI是MRI.在这里,PET是PET.机器学习是机器学习.轻度的认知障碍 轻度的认知障碍更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
989
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
相关概念视频
Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
